New drug plus immunotherapy for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This study tests a new drug (SYS6006) combined with an existing immunotherapy (called Enlonstobart) to see if it works better than the immunotherapy alone for people with advanced solid tumors. It may help shrink or slow the growth of your cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a solid tumor cancer (like breast, lung, or colon) that has spread or cannot be removed with surgery.
- You are in reasonably good general health (able to care for yourself and get up and about).
- You have at least one tumor that can be measured on a scan.
- You have not had an autoimmune disease (like lupus or rheumatoid arthritis).
- You do not have active, uncontrolled infections or serious heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new experimental drug (called SYS6051) in people with advanced solid tumors that have not responded to standard treatments. The goal is to find out if the drug is safe and how well it works, and it might help control your cancer.
This trial is testing an investigational drug called SYS6077 to see if it is safe and tolerable for people with advanced solid tumors that have not responded to standard treatments. The goal is to find out if this drug is a safe option for patients who have run out of other choices.
This study tests a new drug combination (SYS6010 and possibly SYH2051) compared to standard chemotherapy for advanced breast cancer and other solid tumors. It aims to see if this experimental treatment can shrink tumors and help people with EGFR-positive cancers, potentially offering a new option.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
This trial tests a new treatment that combines a drug called SYS6010 with an immunotherapy (Enlonstobart) compared to the usual immunotherapy plus chemo for advanced lung cancer. The goal is to see if this combo works better and helps people with PD-L1 positive lung cancer live longer and feel better.
This trial is testing a new combination treatment, SYS6010 plus enlonstobart, for people with head and neck squamous cell carcinoma that has come back or spread. It aims to see if this combination works better than enlonstobart alone.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.